SHR0302 Tablets

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Non-segmental VitiligoRheumatoid Arthritis

Phase 1

A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

CompletedNCT05392127

Jiangsu HengRui Medicine Co., Ltd.Rheumatoid Arthritis

Start: 2022-07-15End: 2022-08-18Updated: 2022-12-22

Phase 2

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

RecruitingNCT07251595

Jiangsu HengRui Medicine Co., Ltd.Non-segmental Vitiligo

Start: 2025-12-05End: 2027-09-01Target: 176Updated: 2026-02-18

Related Papers

Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis

British Journal of Clinical Pharmacology2023-07-191 citations